CUMYL-CBMICA

CUMYL-CBMICA is a synthetic cannabinoid receptor agonist in the indole-3-carboxamide family. It was first identified in herbal material in 2019 and is distinguished by a cyclobutylmethyl group attached to the indole nitrogen and a cumyl group on the carboxamide. Its identification marked the appearance of a new side-chain motif among synthetic cannabinoids.

Chemistry and identification

CUMYL-CBMICA is 1-(cyclobutylmethyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide. The compound combines an indole-3-carboxamide core with a cyclobutylmethyl side chain and a cumyl amide substituent. It was isolated from herbal material and characterised using GC-MS, LC-high-resolution mass spectrometry, infrared spectroscopy, Raman spectroscopy and NMR (Identification of CUMYL-CBMICA, 2020).

The compound was formally notified through the European Early Warning System after its identification in 2019. The cyclobutylmethyl group was unusual among the synthetic cannabinoids reported at that time.

Pharmacology

A 2021 study examined CUMYL-CBMICA and the related CUMYL-CBMINACA in human CB₁ receptor assays. Both compounds showed cannabinoid receptor binding and activation, although their functional properties differed from those of several earlier cumyl-derived cannabinoids. The study also investigated their human phase I metabolism using liver microsomes and hepatocytes (Haschimi and colleagues, 2021).

The findings support CB₁-mediated activity, but receptor measurements are not a substitute for controlled human observations. They do not establish the intensity or duration of intoxication.

Metabolism

The 2021 study identified several phase I metabolites for CUMYL-CBMICA. The main pathways included oxidation of the cyclobutylmethyl side chain and modifications to the indole and cumyl portions of the molecule. The researchers proposed metabolites that may be useful for forensic detection when the parent compound is no longer present in a biological sample.

Metabolic findings from CUMYL-CBMINACA are relevant for comparison, but the two compounds have different heterocyclic cores and should remain analytically distinct.

Reported effects and clinical evidence

Reliable descriptions of the human experience with CUMYL-CBMICA are scarce. The original identification and metabolism studies were analytical and laboratory investigations, not clinical trials. No well-characterised case series establishes a specific pattern of symptoms after confirmed exposure.

Toxicity and research limitations

Its acute toxic range, dependence potential and long-term effects have not been established in humans. The available literature confirms that the compound has appeared in herbal material and has cannabinoid receptor activity, without fully establishing its clinical risks.

Related compounds

CUMYL-CBMICA is related to CUMYL-BICA and CUMYL-PICA through its cumyl-indole-carboxamide structure. It is also related to CUMYL-CBMINACA, which contains an indazole rather than an indole core.